MedPath

Phase II study evaluating efficacy and safety of peripheral blood stem cell harvest with bortezomib for multiple myeloma

Not Applicable
Conditions
Multiple Myeloma
Registration Number
JPRN-UMIN000010258
Lead Sponsor
Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients HIV-HBs-and HCV-positive. 2) Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 3) Patients with a history of active malignancy. 4) Patients with severe psychiatric disorders. 5) Patients with pregnancy or lactation. 6) Those who are considered as inappropriate to register by attending physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath